New Nordic Healthbrands AB Logo

New Nordic Healthbrands AB

Develops and markets herbal supplements & beauty products for natural wellness consumers globally.

NNH | ST

Overview

Corporate Details

ISIN(s):
SE0001838038
LEI:
213800JGTLNSKRD49G44
Country:
Sweden
Address:
SÖDRA FÖRSTADSGATAN 3, 211 43 MALMÖ
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

New Nordic Healthbrands AB is a company specializing in the development, marketing, and sale of herbal-based dietary supplements, natural remedies, and beauty products. Since its establishment in 1990, the company has focused on leveraging its expertise in medicinal plants to create innovative products that address specific health and beauty needs. New Nordic emphasizes scientific validation and quality control, analyzing all ingredients in controlled laboratories to ensure the safety and effectiveness of its offerings. The company markets its distinct brands globally to consumers seeking natural wellness solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all New Nordic Healthbrands AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for New Nordic Healthbrands AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for New Nordic Healthbrands AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-16 Karl Kristian Bergman Jensen Other Sell 5,000 115,000.00 SEK
2025-03-12 Karl Kristian Bergman Jensen Other Sell 5,000 74,900.00 SEK
2025-03-11 Karl Kristian Bergman Jensen Other Sell 5,000 79,500.00 SEK
2025-03-05 Karl Kristian Bergman Jensen Other Sell 5,000 81,250.00 SEK
2025-01-22 Karl Kristian Bergman Jensen Other Sell 5,000 73,300.00 SEK
2025-01-21 Karl Kristian Bergman Jensen Other Sell 5,000 73,500.00 SEK
2025-01-20 Karl Kristian Bergman Jensen Other Sell 5,000 73,500.00 SEK
2024-12-27 Karl Kristian Bergman Jensen Other Sell 5,000 74,050.00 SEK
2024-12-18 Karl Kristian Bergman Jensen Other Sell 5,000 73,300.00 SEK
2024-09-06 Karl Kristian Bergman Jensen Other Sell 4,000 61,960.00 SEK

Peer Companies

Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR
ESSA Pharma Inc. Logo
Develops novel small molecule drugs to treat castration-resistant prostate cancer.
United States of America
EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
United States of America
ESLA
Eton Pharmaceuticals, Inc. Logo
Develops and commercializes innovative treatments for rare pediatric diseases.
United States of America
ETON
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea
206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Developing targeted, extended-release therapies for GI and musculoskeletal diseases.
United States of America
EPRX
eureKING Logo
A SPAC acquiring European biomanufacturers to create a large-scale CDMO for advanced therapies.
France
KINGS
EuroAPI Logo
Global manufacturer of APIs and CDMO services for human and animal health partners worldwide.
France
EAPI
Eurobio Scientific Logo
Develops & distributes specialty IVD tests for oncology, transplant & infectious diseases.
France
ALERS
European Institute of Science AB Logo
Manufactures diagnostic assays and point-of-care instruments for the veterinary health market.
Sweden
EURI B

Talk to a Data Expert

Have a question? We'll get back to you promptly.